Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose Simvastatin in Refractory GI Cancer
NCT03086291Phase 1Unknown
- Sponsor
- Samsung Medical Center
- Start
- Jan 2018
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of simvastatin in gastric cancer (GC) and colorectal cancer (CRC), sponsored by Samsung Medical Center. Primary endpoint: Maximum Tolerated Dose at 12 months. Status: unknown.
02
Drugs
simvastatin
03
Conditions
gastric cancer (GC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03086291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03086291.